Fosamax Osteonecrosis of the Jaw Settlement: Settlement Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

For decades, the general health and science information landscape has provided foundational guidance on medication safety and patient awareness. Within this legacy, broad educational efforts have emphasized the importance of understanding potential side effects associated with long-term pharmaceutical use, particularly for chronic conditions. This context has historically served to empower patients and clinicians with knowledge about therapeutic benefits and risks, fostering informed decision-making in routine medical care. As this informational framework evolved, a more focused concern emerged regarding specific adverse outcomes linked to prolonged medication exposure. Among these, the association between bisphosphonate therapy—commonly prescribed for osteoporosis—and rare but serious bone complications has drawn increasing attention. This shift from general health education to targeted risk awareness naturally leads to a critical occupational exposure consideration. For individuals who have been prescribed medications such as Fosamax over extended periods, the potential for developing osteonecrosis of the jaw represents a significant clinical and legal concern. The transition from broad health literacy to this specific exposure scenario underscores the need for clear settlement criteria, enabling affected patients to navigate the complexities of compensation and medical follow-up with the same clarity that general health information once provided.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This section outlines the clinical presentation, mechanistic pathways, and settlement-related considerations for affected patients, based solely on the provided evidence. Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms varies from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the medication, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The precise mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully elucidated, but research provides insights into jawbone-specific responses. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate (the active ingredient in Fosamax) found that most jawbone characteristics in ovariectomized (OVX) and treatment groups were not significantly different from those of the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). The surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in the OVX rat groups compared to the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). All tissue mineral density parameters rapidly increased up to 60 μm from the periodontal ligament surrounding teeth regardless of the treatment groups (https://pubmed.ncbi.nlm.nih.gov/40345077/). Treatments using each therapeutic agent and its combination did not substantially change those characteristics of jawbones in OVX rats (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings are different from those of lumbar vertebrae in the same rats that showed a significant bone alteration by OVX and treatments (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the jawbone may have unique responses to bisphosphonate therapy, potentially contributing to the development of ONJ.

Adequacy of Warnings and Settlement Considerations

The prescribing information for Fosamax includes a warning about osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also states that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of these warnings is a key consideration in legal contexts, as patients may argue that they were not sufficiently informed of the risk. For patients affected by ONJ, settlement criteria typically involve establishing a causal link between Fosamax use and the development of ONJ. Key factors include the timeline between exposure and documented harm, as the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the presence of known risk factors, such as invasive dental procedures or concomitant therapies, may influence settlement outcomes. The evidence suggests that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), which may be relevant in assessing whether adequate warnings were provided. The timeline for ONJ development is variable, with symptoms appearing from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear causal relationship in individual cases. The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), which is an important factor in settlement evaluations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. A known adverse effect is osteonecrosis of the jaw (ONJ), a condition of exposed, non-healing bone in the jaw. ONJ can occur spontaneously or after dental procedures in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the settlement criteria for Fosamax-related ONJ?

Settlement criteria typically require establishing a causal link between Fosamax use and ONJ, considering the timeline of exposure (symptoms can appear from one day to several months after starting the drug) and presence of risk factors such as invasive dental procedures or concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adequacy of warnings is also a key factor.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.